A Multicenter, Open-label Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 Capsules in Patients With Primary IgA Nephropathy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patients with primary IgA nephropathy who completed treatment in Study HRS-5965-305, or who prematurely discontinued study drug during the maintenance phase following initiation of rescue therapy;
• Understand the research procedures and methods, voluntarily participate in this trial and sign the informed consent form in person.
Locations
Other Locations
China
Peking University First Hospital
RECRUITING
Beijing
Contact Information
Primary
Yanfang Zou
yanfang.zou@hengrui.com
+0518-82342973
Time Frame
Start Date: 2026-07-06
Estimated Completion Date: 2029-11
Participants
Target number of participants: 380
Treatments
Experimental: HRS-5965 Capsules
Related Therapeutic Areas
Sponsors
Leads: Chengdu Suncadia Medicine Co., Ltd.